SG11201803913RA - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents
Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of painInfo
- Publication number
- SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- opioid
- oxide derivative
- pct
- cambridgeshire
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, -, Organization IIIM1411011101010111110101111 1010111111111110111001101011111110111011# International Bureau ... ...... .Y1 j ..... ...,/ (10) International Publication Number International Publication Date WO 2017/085502 Al 26 May 2017(26.05.2017) WIPO I PCT (51) (21) (22) (25) (26) (30) (71) (71) (72) (74) International Patent Classification: A61K 9/70 (2006.01) A61P A61K 31/485 (2006.01) International Application Number: International Filing Date: Filing Language: Publication Language: Priority Data: 1520390.4 19 November 2015 Applicant: EURO-CELTIQUE Jean Piret, L-2350 Luxembourg (LU). Applicant (for SD only): GORDON, C/O Marks & Clerk LLP, 62-68 Cambridgeshire CB2 1LA (GB). 18 November (81) Designated States (unless otherwise indicated, for every 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB2016/053600 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 2016 (18.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (19.11.2015) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, S.A. [LU/LU]; 1, me GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Kirsteen [GB/GB]; DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Hills Road, Cambridge LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Mundipharma Research GW, KM, ML, MR, NE, SN, TD, TG). Park, Milton Road, Cam- (GB). Published: with international search report (Art. 21(3)) LLP; 62-68 Hills Road, 1LA (GB). Inventor: WHITELOCK, Steve; Limited, 191 Cambridge Science bridge Cambridgeshire CB4 OGW Agent: MARKS & CLERK Cambridge Cambridgeshire CB2 = Title: ABUSE RESISTANT TRANSDERMAL NON-TRANSDERMALLY DELIVERED 32 ----)2i : The present invention provides a transdermal delivery device comprising comprises a N-oxide derivative (54) N composition DELIVERY DEVICES AND COMPOSITIONS N-OXIDE DERIVATIVE OF AN OPIOID ANTAGONIST 34 32 31 33 COMPRISING AN OPIOID AGONIST AND FOR THE TREATMENT OF PAIN 30 / 35 a pharmaceutical composition, wherein said an opioid agonist or salt thereof. - A V' eek( 1) 1 V i)' az, co 'D V (> el ° a V J . . g a ',' a 1 7 a ‘) to O ci- (.•_, 0 el. 0 1-1 ei © ir) ir) ot 0 IN Il 0 (57) C ,////// Z/Z/Z/Z. - \ Figure 4 of an opioid antagonist, or a salt thereof, and
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1520390.4A GB201520390D0 (en) | 2015-11-19 | 2015-11-19 | Composition |
PCT/GB2016/053600 WO2017085502A1 (en) | 2015-11-19 | 2016-11-18 | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803913RA true SG11201803913RA (en) | 2018-06-28 |
Family
ID=55133015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803913RA SG11201803913RA (en) | 2015-11-19 | 2016-11-18 | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180344726A1 (en) |
EP (1) | EP3377048B1 (en) |
JP (1) | JP2018534319A (en) |
KR (1) | KR20180074797A (en) |
CN (1) | CN108601747A (en) |
AU (1) | AU2016355113A1 (en) |
BR (1) | BR112018009886A2 (en) |
CA (1) | CA3005775A1 (en) |
ES (1) | ES2799516T3 (en) |
GB (1) | GB201520390D0 (en) |
IL (1) | IL259457A (en) |
MX (1) | MX2018006157A (en) |
SG (1) | SG11201803913RA (en) |
WO (1) | WO2017085502A1 (en) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722928A (en) * | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US20040033255A1 (en) * | 2002-06-10 | 2004-02-19 | Baker Carl J. | Transdermal delivery device disposal system |
NZ549576A (en) * | 2004-02-23 | 2010-04-30 | Euro Celtique Sa | Abuse resistance opioid transdermal delivery device using microspheres of opiate antagonist |
JP2010510326A (en) * | 2006-11-22 | 2010-04-02 | プロジェニックス ファーマスーティカルス インコーポレーテッド | N-oxides of 4,5-epoxy-morphinanium analogs |
WO2009067275A1 (en) * | 2007-11-21 | 2009-05-28 | Progenics Pharmaceuticals, Inc | N-oxides of 4,5-epoxy-morphinanium analogs |
CA2718943A1 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
JP2013523780A (en) * | 2010-04-02 | 2013-06-17 | オールトランツ インコーポレイティド | Abuse deterrent transdermal preparations of opiate agonists and agonist-antagonists |
-
2015
- 2015-11-19 GB GBGB1520390.4A patent/GB201520390D0/en not_active Ceased
-
2016
- 2016-11-18 ES ES16801029T patent/ES2799516T3/en active Active
- 2016-11-18 SG SG11201803913RA patent/SG11201803913RA/en unknown
- 2016-11-18 MX MX2018006157A patent/MX2018006157A/en unknown
- 2016-11-18 CA CA3005775A patent/CA3005775A1/en not_active Abandoned
- 2016-11-18 CN CN201680067561.0A patent/CN108601747A/en active Pending
- 2016-11-18 BR BR112018009886A patent/BR112018009886A2/en not_active Application Discontinuation
- 2016-11-18 EP EP16801029.6A patent/EP3377048B1/en active Active
- 2016-11-18 US US15/777,333 patent/US20180344726A1/en not_active Abandoned
- 2016-11-18 KR KR1020187017271A patent/KR20180074797A/en unknown
- 2016-11-18 JP JP2018526061A patent/JP2018534319A/en active Pending
- 2016-11-18 AU AU2016355113A patent/AU2016355113A1/en not_active Abandoned
- 2016-11-18 WO PCT/GB2016/053600 patent/WO2017085502A1/en active Application Filing
-
2018
- 2018-05-17 IL IL259457A patent/IL259457A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2018006157A (en) | 2019-04-04 |
AU2016355113A1 (en) | 2018-05-24 |
CA3005775A1 (en) | 2017-05-26 |
IL259457A (en) | 2018-07-31 |
WO2017085502A1 (en) | 2017-05-26 |
ES2799516T3 (en) | 2020-12-18 |
EP3377048B1 (en) | 2020-04-22 |
GB201520390D0 (en) | 2016-01-06 |
JP2018534319A (en) | 2018-11-22 |
CN108601747A (en) | 2018-09-28 |
US20180344726A1 (en) | 2018-12-06 |
KR20180074797A (en) | 2018-07-03 |
EP3377048A1 (en) | 2018-09-26 |
BR112018009886A2 (en) | 2018-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804934PA (en) | Novel Compounds | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201408279QA (en) | Social sharing of security information in a group | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |